Re: Sangamo BioSciences Announces New Gene Therapy Clinical Development Program for Treatment Of Hemophilia A
Sometimes the tortoise wins...
This new therapeutic comprises an adeno-associated virus (AAV) cDNA human Factor 8 (hF8) construct driven by Sangamo's proprietary synthetic liver specific promoter, which in preclinical studies is at least three times more potent than existing AAV-based cDNA constructs currently under evaluation for the treatment of hemophilia A.
Sangamo BioSciences, Inc. (PRNewsFoto/Sangamo BioSciences, Inc.)
"We have compelling preclinical data from this AAV cDNA therapeutic which suggest its potential to be 'best in class' in this highly competitive field," said Geoff Nichol, M.B., Ch.B., Sangamo's executive vice president of research and development